Last reviewed 2026-04-23 · How we verify

Liberal platelet transfusion

Post Graduate Institute of Medical Education and Research, Chandigarh · Phase 3 active Biologic

Liberal platelet transfusion is a Biologic drug developed by Post Graduate Institute of Medical Education and Research, Chandigarh. It is currently in Phase 3 development for Thrombocytopenia in hematologic malignancies, Thrombocytopenia in patients undergoing chemotherapy, Prevention of bleeding in severely thrombocytopenic patients.

Liberal platelet transfusion increases circulating platelet counts to prevent or treat bleeding in thrombocytopenic patients.

Liberal platelet transfusion increases circulating platelet counts to prevent or treat bleeding in thrombocytopenic patients. Used for Thrombocytopenia in hematologic malignancies, Thrombocytopenia in patients undergoing chemotherapy, Prevention of bleeding in severely thrombocytopenic patients.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Liberal platelet transfusion
Sponsor	Post Graduate Institute of Medical Education and Research, Chandigarh
Modality	Biologic
Therapeutic area	Hematology
Phase	Phase 3

Mechanism of action

This is a transfusion strategy that administers platelets prophylactically or therapeutically to patients with low platelet counts (thrombocytopenia). The transfused platelets restore hemostatic function by increasing platelet numbers above critical thresholds, reducing spontaneous bleeding risk. The 'liberal' approach typically involves transfusing at higher platelet count thresholds compared to restrictive strategies.

Approved indications

Thrombocytopenia in hematologic malignancies
Thrombocytopenia in patients undergoing chemotherapy
Prevention of bleeding in severely thrombocytopenic patients

Common side effects

Alloimmunization
Transfusion-related acute lung injury (TRALI)
Febrile non-hemolytic transfusion reaction
Bacterial contamination/sepsis
Volume overload

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Liberal platelet transfusion CI brief — competitive landscape report
Liberal platelet transfusion updates RSS · CI watch RSS
Post Graduate Institute of Medical Education and Research, Chandigarh portfolio CI

Frequently asked questions about Liberal platelet transfusion

What is Liberal platelet transfusion?

Liberal platelet transfusion is a Biologic drug developed by Post Graduate Institute of Medical Education and Research, Chandigarh, indicated for Thrombocytopenia in hematologic malignancies, Thrombocytopenia in patients undergoing chemotherapy, Prevention of bleeding in severely thrombocytopenic patients.

How does Liberal platelet transfusion work?

Liberal platelet transfusion increases circulating platelet counts to prevent or treat bleeding in thrombocytopenic patients.

What is Liberal platelet transfusion used for?

Liberal platelet transfusion is indicated for Thrombocytopenia in hematologic malignancies, Thrombocytopenia in patients undergoing chemotherapy, Prevention of bleeding in severely thrombocytopenic patients.

Who makes Liberal platelet transfusion?

Liberal platelet transfusion is developed by Post Graduate Institute of Medical Education and Research, Chandigarh (see full Post Graduate Institute of Medical Education and Research, Chandigarh pipeline at /company/post-graduate-institute-of-medical-education-and-research-chandigarh).

What development phase is Liberal platelet transfusion in?

Liberal platelet transfusion is in Phase 3.

What are the side effects of Liberal platelet transfusion?

Common side effects of Liberal platelet transfusion include Alloimmunization, Transfusion-related acute lung injury (TRALI), Febrile non-hemolytic transfusion reaction, Bacterial contamination/sepsis, Volume overload.

Manufacturer: Post Graduate Institute of Medical Education and Research, Chandigarh — full pipeline
Therapeutic area: All drugs in Hematology
Indication: Drugs for Thrombocytopenia in hematologic malignancies
Indication: Drugs for Thrombocytopenia in patients undergoing chemotherapy
Indication: Drugs for Prevention of bleeding in severely thrombocytopenic patients

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing